New hope for rare paralysis: drug combo targets toxic cholesterol byproducts
NCT ID NCT02314208
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tested three drugs (Xenbilox, Tahor, and Resveratrol) in 12 adults with a rare genetic form of spastic paraplegia called SPG5. The goal was to lower levels of harmful oxysterols—toxic byproducts of cholesterol—that build up in the body. The approach aims to reduce disease burden, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPASTIC PARAPLEGIA, HEREDITARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pitié-Salpêtrière Hospital
Paris, France
Conditions
Explore the condition pages connected to this study.